Abstract
The autologous bone substitutes are the gold standard of orthopedic surgery for the treatment of severe losses of substance. Nevertheless there are different issues, from co-morbidity of the donor site, the limited quantity and poor osteogenic properties. To overcome these limits the bank of the skeletal muscle tissue of the Rizzoli Institutes in cooperation with FIN-ceramic Faenza SpA have developed DBSint: a new synthetic bone composite, equipped with biomimetic and osteoinductive properties, consisting of demineralized bone matrix conveyed by nanostructured hydroxyapatite enriched with magnesium. The DBSint has recently been evaluated with a clinical preliminary study with the purpose to analyze the ability to form new bone tissue and the time necessary to determine bone repair. We enrolled 36 patients with indication to perform a valgus osteotomy of the tibia, divided into 3 groups, respectively, treated with nano hydroxyapatite structured in the form of paste (SINTlife) currently on the market, the cortico-cancellous bone chips provided by the BTM-IOR, and finally DBSint. There were no adverse effects, we performed biopsies and histological exam, and radiographic assessment, respectively, at 40 days and 6 months after treatment, showing that the DBSint is able to promote a fast bone regeneration, higher than in the two groups treated with Sintlife and homologous bone.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
